Table of Content
1 Introduction
This chapter will discuss report details and nothing of actual content
1.1 Report scope
1.2 Inclusion, Exclusion criteria and Assumptions
1.3 What questions will be addressed in the report
2 Executive Summary
3 Disease Landscape
3.1 Therapy Area Introduction
3.2 Symptoms
3.3 Diagnosis, Scales and Grading
3.4 Etiology
3.5 Pathophysiology
3.6 Prognosis
3.7 Epidemiology
4 Treatment Overview
4.1 Treatment algorithm with 1, 2, and 3 line of treatment in detail
4.2 Comorbidities and Complications
5 Key Marketed Products
5.1 Overview
5.2 Catalyst
6 Pipeline Landscape Assessment
6.1 Overview
6.2 Pipeline Development Landscape
6.3 Molecular Targets in the Pipeline
6.4 Pre-Clinical Molecules
6.5 Attribute Analysis
7 Clinical Trials Analytics
7.1 Clinical Trial Failure Rates
7.2 Clinical Trial Duration
8 Multi-scenario Market Forecast to 2027
8.1 Global Market Analysis
8.1.1 Regional Market Analysis
8.1.1.1 USA
8.1.1.2 Canada
8.1.1.3 UK
8.1.1.4 Germany
8.1.1.5 France
8.1.1.6 Spain
8.1.1.7 Italy
8.1.1.8 Japan
8.1.1.9 South Korea
8.1.1.10 Brazil
8.1.1.11 Russia
8.1.1.12 India
8.1.1.13 China
8.1.2 Market size by Drug Class
8.2 Market Dynamics
8.3 Regulatory Landscape
8.4 Generic Penetration
9 R&D Strategies
9.1 Overview
9.2 R&D strategies from a business perspective
9.3 Clinical Trial Design (inclusion of new biomarkers, endpoints, and measurement metrics)
9.4 Label Expansions into Earlier Lines of Therapy
10 Company Analysis and Positioning
10.1 Competitive Assessment
10.2 Company Evaluation Matrix (BCG Matrix)
10.2.1 Stars
10.2.2 Emerging leaders
10.2.3 Pervasive companies
10.2.4 Participants
10.3 Company information (Funding/investment analysis)
10.3.1 Key players
10.3.2 Established players
10.3.3 Upcoming/Start-ups
11 Strategic Consolidations
11.1 Licensing Deals
11.2 Co-development Deals
12 Primary research analysis/ KOL Insights
12.1 Analysis can be on current state of the disease management / development
12.2 Unmet needs pertaining to treatment
12.3 KOL Insights (What does the KOLs expect from the big companies, KOLs willingness if the client is already in advanced stage of asset development)
13 Key Opportunities
13.1 Unmet Needs
13.2 Opportunity Assessment